5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology

5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology

Exam Focus: Neurologic, psychiatric, and musculoskeletal disorders encompass complex neurochemical transmission circuits, autoimmune targeting of central and peripheral structures, and articular remodeling dynamics. Candidates must master dopaminergic pathways in schizophrenia, basal ganglia motor circuitry in Parkinson's disease, the molecular cascade of gouty inflammation (NLRP3 inflammasome), and the pathological distinctions between rheumatoid arthritis and osteoarthritis.

---

Neurologic Pathophysiology

1. Cerebrovascular Disease: Ischemic vs Hemorrhagic Stroke

Cerebrovascular accidents (CVAs) result in rapid loss of focal neurological function caused by vascular disruption of cerebral perfusion:

+-------------------------------------------------------------------------+
|                   CEREBROVASCULAR ACCIDENT TAXONOMY                     |
+-------------------------------------------------------------------------+
|                                                                         |
|  [ISCHEMIC STROKE] (~85%)               [HEMORRHAGIC STROKE] (~15%)     |
|  - Large Artery Atherothromboembolism   - Intracerebral Hemorrhage (ICH)|
|  - Cardioembolism (Atrial Fibrillation)   (Charcot-Bouchard rupture)    |
|  - Small Vessel Lacunar Infarcts        - Subarachnoid Hemorrhage (SAH) |
|  - Core Infarct vs Ischemic Penumbra      (Berry aneurysm rupture)      |
|                                                                         |
+-------------------------------------------------------------------------+

• Ischemic Stroke ($\sim 85%$ of strokes):
  • Core Infarct vs Penumbra: The central core infarct undergoes irreversible liquefactive necrosis within minutes of severe hypoperfusion ($< 10\text{ mL}/100\text{ g tissue/min}$). Surrounding the core is the ischemic penumbra—hypoperfused, electrically silent tissue that remains structurally viable if reperfusion is achieved rapidly via intravenous thrombolysis (alteplase/tenecteplase within $4.5\text{ hours}$) or endovascular thrombectomy (within $6\text{ to }24\text{ hours}$).
  • Excitotoxicity Cascade: Hypoxia depletes neuronal ATP, collapsing $\text{Na}^+/\text{K}^+$-ATPase pump activity. Neurons depolarize, triggering massive pathological extracellular release of glutamate. Excessive activation of postsynaptic NMDA and AMPA receptors induces massive intracellular calcium influx, activating intracellular proteases, phospholipases, and endonucleases that execute necrotic and apoptotic cell death.
• Hemorrhagic Stroke ($\sim 15%$ of strokes):
  • Intracerebral Hemorrhage (ICH): Rupture of small penetrating arteries damaged by chronic hypertension (microaneurysms of Charcot-Bouchard in lenticulostriate branches supplying the basal ganglia, thalamus, and pons).
  • Subarachnoid Hemorrhage (SAH): Rupture of saccular ("berry") aneurysms in the Circle of Willis (most commonly at the anterior communicating artery bifurcation). Classically presents with sudden-onset "worst headache of life" (thunderclap headache) and meningismus.
• Transient Ischemic Attack (TIA): Transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia without acute tissue infarction on neuroimaging. Although symptoms typically resolve within 1 hour, TIAs carry high immediate stroke risk (stratified using the $ABCD^2$ Score).

2. Epilepsy and Seizure Ictogenesis

Seizures represent transient signs and symptoms resulting from abnormal, excessive, or synchronous neuronal activity in the brain.

• Neurochemical Imbalance: Fundamental disequilibrium between excessive neuronal excitation (glutamatergic transmission acting on NMDA/AMPA receptors and voltage-gated sodium/calcium channels) and deficient neuronal inhibition (GABAergic transmission acting on $GABA_A$ receptor-gated chloride channels).
• Classification (ILAE Guidelines):
  • Focal Seizures: Originate within neural networks limited to one cerebral hemisphere. Subdivided into Focal Aware (consciousness preserved) and Focal Impaired Awareness. May progress to bilateral tonic-clonic activity.
  • Generalized Seizures: Originate at some point within and rapidly engage bilaterally distributed cerebral networks (e.g., Absence [petit mal; $3\text{ Hz}$ spike-and-wave discharge on EEG], Generalized Tonic-Clonic [grand mal], Myoclonic, Atonic).
• Status Epilepticus: Medical emergency defined as continuous seizure activity lasting $\ge 5\text{ minutes}$, or two or more discrete seizures without complete recovery of baseline consciousness between episodes. Prolonged status ($> 30\text{ minutes}$) produces excitotoxic neuronal injury, hyperpyrexia, systemic metabolic acidosis, and autonomic collapse. Initial treatment: IV benzodiazepine (lorazepam or midazolam) followed by IV antiepileptic loading (fosphenytoin, levetiracetam, or sodium valproate).

3. Neurodegenerative Disorders

+-------------------------------------------------------------------------+
|                   BASAL GANGLIA CIRCUITRY IN PARKINSON'S                |
+-------------------------------------------------------------------------+
|                                                                         |
|  Substantia Nigra Pars Compacta (SNc) ---[LOSS OF DOPAMINE]             |
|         |                                                               |
|         v                                                               |
|  [D1 Direct Pathway] (Loss of Motor Facilitation)                       |
|  [D2 Indirect Pathway] (Loss of Motor Inhibition Suppression)           |
|         |                                                               |
|         v                                                               |
|  Excessive GPi / SNr Inhibitory Output to Ventral Thalamus              |
|         |                                                               |
|         v                                                               |
|  Profound Suppression of Motor Cortex -> BRADYKINESIA & RIGIDITY        |
|                                                                         |
+-------------------------------------------------------------------------+

---

Psychiatric Pathophysiology

1. Schizophrenia: Dopaminergic Pathways and Glutamate Hypofunction

Schizophrenia is a complex neuropsychiatric disorder characterized by profound disturbances in perception, thought, emotion, and behavior.

+-------------------------------------------------------------------------+
|                 DOPAMINERGIC PATHWAYS IN SCHIZOPHRENIA                  |
+-------------------------------------------------------------------------+
|                                                                         |
|  1. Mesolimbic Pathway (VTA -> Nucleus Accumbens):                      |
|     HYPERACTIVITY -> POSITIVE Symptoms (Delusions, Hallucinations)     |
|                                                                         |
|  2. Mesocortical Pathway (VTA -> Prefrontal Cortex):                    |
|     HYPOACTIVITY -> NEGATIVE & COGNITIVE Symptoms (Avolition, Flatness) |
|                                                                         |
|  3. Nigrostriatal Pathway (Substantia Nigra -> Caudate/Putamen):        |
|     D2 Antagonism -> Extrapyramidal Symptoms (EPS), Parkinsonism, TD    |
|                                                                         |
|  4. Tuberoinfundibular Pathway (Hypothalamus -> Anterior Pituitary):    |
|     D2 Antagonism -> Hyperprolactinemia (Galactorrhea, Amenorrhea)      |
|                                                                         |
+-------------------------------------------------------------------------+

• Dopamine Hypothesis:
  • Mesolimbic Pathway: Hyperactivity of $D_2$ receptor-mediated dopaminergic transmission in the ventral tegmental area (VTA) projecting to the nucleus accumbens drives positive symptoms (auditory hallucinations, persecutory delusions, conceptual disorganization).
  • Mesocortical Pathway: Hypoactivity of $D_1$ receptor-mediated dopaminergic transmission projecting from the VTA to the dorsolateral prefrontal cortex underlies negative symptoms (avolition, alogia, affective flattening, anhedonia) and cognitive deficits (executive dysfunction, working memory impairment).
  • Nigrostriatal Pathway: Regulates motor planning. Dopamine $D_2$ receptor blockade by antipsychotics induces extrapyramidal symptoms (acute dystonia, akathisia, pseudoparkinsonism) and, with long-term exposure, tardive dyskinesia ($D_2$ receptor upregulation and supersensitivity).
  • Tuberoinfundibular Pathway: Dopamine acts as prolactin-inhibiting factor (PIF). Blockade of $D_2$ receptors removes tonic inhibition of lactotrophs in the anterior pituitary, causing hyperprolactinemia (galactorrhea, gynecomastia, amenorrhea, sexual dysfunction, bone demineralization).
• Glutamate NMDA Receptor Hypofunction Model: Hypofunction of NMDA receptors on GABAergic interneurons in the prefrontal cortex leads to disinhibition of downstream excitatory circuits, causing secondary mesolimbic dopamine excess and mesocortical dopamine deficit.

2. Major Depressive Disorder (MDD) and Bipolar Disorder

• Major Depressive Disorder (MDD):
  • Monoamine Hypothesis: Functional depletion of central serotonin ($5\text{-HT}$), norepinephrine (NE), and dopamine (DA) neurotransmission within limbic and prefrontal circuits.
  • Neurotrophic and Neuroplastic Hypothesis: Chronic stress elevates glucocorticoids, downregulating Brain-Derived Neurotrophic Factor (BDNF) expression, leading to synaptic pruning and dendritic atrophy within the hippocampus and prefrontal cortex.
  • Neuroendocrine Dysfunction: Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis, impaired glucocorticoid receptor feedback, and elevated pro-inflammatory cytokines (IL-6, TNF-$\alpha$).
  • Diagnostic Criteria (DSM-5 / SIGECAPS): Depressed mood or loss of interest/pleasure (anhedonia) plus $\ge 4$ symptoms for $\ge 2\text{ weeks}$: Sleep changes, Interest loss, Guilt/worthlessness, Energy deficit, Concentration impairment, Appetite/weight shifts, Psychomotor agitation/retardation, Suicidal ideation.
• Bipolar Disorders:
  • Bipolar I: Characterized by at least one lifetime manic episode (severe, persistent elevated or irritable mood with grandiosity, decreased need for sleep, pressured speech, racing thoughts, and severe psychosocial impairment lasting $\ge 1\text{ week}$ or requiring hospitalization).
  • Bipolar II: Characterized by at least one hypomanic episode (lasting $\ge 4\text{ days}$, without marked functional impairment or psychosis) and at least one major depressive episode.
  • Pathophysiology: Disruptions in cellular signal transduction systems (G-protein coupling, protein kinase C, inositol phosphate signaling), altered circadian clock gene expression, and intracellular calcium handling aberrancies.

---

Musculoskeletal and Connective Tissue Pathophysiology

+-------------------------------------------------------------------------+
|                 RHEUMATOID ARTHRITIS VS OSTEOARTHRITIS                  |
+-------------------------------------------------------------------------+
|                                                                         |
|  [RHEUMATOID ARTHRITIS]                 [OSTEOARTHRITIS]                |
|  - Autoimmune, Systemic                 - Mechanical, Non-Inflammatory  |
|  - Synovial Pannus Formation            - Cartilage Fibrillation & Loss |
|  - Anti-CCP & RF Autoantibodies         - Subchondral Sclerosis, Cysts  |
|  - Symmetrical Small Joints (MCP/PIP)   - Asymmetrical Large Joints, DIP|
|  - Sparing: DIP Joints                  - Nodes: Heberden's & Bouchard's|
|  - Morning Stiffness > 1 hour           - Morning Stiffness < 30 minutes|
|                                                                         |
+-------------------------------------------------------------------------+

1. Rheumatoid Arthritis vs Osteoarthritis

• Rheumatoid Arthritis (RA): Chronic systemic autoimmune inflammatory disease targeting the synovial membrane (synovitis):
  • Autoimmunity: Environmental triggers (smoking) in genetically predisposed individuals (HLA-DRB1 shared epitope) induce post-translational citrullination of self-proteins. Citrullinated peptides are presented to $CD4^+$ T cells, which stimulate B cells to produce Anti-Citrullinated Protein Antibodies (anti-CCP / ACPA) and Rheumatoid Factor (RF) (IgM directed against the Fc portion of IgG).
  • Pannus Formation: Hyperplastic synovial tissue forms a destructive, invasive fibrovascular mass (pannus) composed of fibroblast-like synoviocytes, macrophages, and inflammatory cells that releases TNF-$\alpha$, IL-1, IL-6, and matrix metalloproteinases (MMPs), aggressively eroding articular cartilage and underlying subchondral bone.
  • Clinical Pattern: Symmetrical polyarthritis predominantly involving small joints of the hands and feet (MCP, PIP, wrists, MTP joints), characteristically sparing the distal interphalangeal (DIP) joints. Prolonged morning stiffness lasting $> 1\text{ hour}$ that improves with joint movement.
• Osteoarthritis (OA): Progressive, non-systemic degenerative joint disease characterized by biomechanical failure of articular cartilage:
  • Pathophysiology: Repetitive mechanical loading and chondrocyte senescence alter cartilage homeostasis. Chondrocytes secrete degradative enzymes (MMP-13, ADAMTS-4/5 aggrecanases) that degrade type II collagen and proteoglycans, causing cartilage surface fibrillation, fissuring, and full-thickness erosion.
  • Bone Remodeling: Loss of cartilage increases stress on underlying bone, producing subchondral bone sclerosis, subchondral bone cysts, and peripheral bone outgrowths (osteophytes).
  • Clinical Pattern: Asymmetrical joint involvement of weight-bearing joints (knees, hips, lumbar spine) and hands (DIP joints: Heberden's nodes; PIP joints: Bouchard's nodes). Joint pain characteristically worsens with weight-bearing activity and is relieved by rest. Morning stiffness is brief ($< 30\text{ minutes}$).

2. Gout and Crystal-Induced Arthropathies

• Pathophysiology of Hyperuricemia: Serum uric acid represents the end-product of purine metabolism (catalyzed by xanthine oxidase). Hyperuricemia is defined as serum urate $> 400,\mu\text{mol/L}$ ($> 6.8\text{ mg/dL}$), exceeding the physiological solubility limit of monosodium urate (MSU).
  • Renal Underexcretion ($> 90%$ of cases): Impaired clearance via renal tubular transporters (URAT1, GLUT9); worsened by CKD, volume depletion, and medications (thiazide and loop diuretics, low-dose aspirin, calcineurin inhibitors, pyrazinamide, ethambutol).
  • Metabolic Overproduction ($< 10%$ of cases): Purine-rich diet, alcohol excess (increases urate production and competes for renal tubular excretion via lactate), myeloproliferative disorders, tumor lysis syndrome.
• The NLRP3 Inflammasome Cascade:
  1. Supersaturation precipitates needle-shaped monosodium urate (MSU) crystals with negative birefringence into the synovial space.
  2. Synovial resident macrophages phagocytose MSU crystals, triggering lysosomal rupture and intracellular assembly of the NLRP3 Inflammasome protein complex.
  3. NLRP3 activates Caspase-1, which cleaves pro-IL-1$\beta$ into mature, active Interleukin-1 beta (IL-1$\beta$).
  4. Secreted IL-1$\beta$ binds to endothelial IL-1 receptors, triggering massive secretion of chemokines (IL-8) that recruit waves of neutrophils into the joint space.
  5. Neutrophils phagocytose crystals, release inflammatory leukotrienes and free radicals, generating acute, excruciating synovitis (podagra at the 1st MTP joint).

3. Bone Remodeling and Osteoporosis

• Bone Remodeling Dynamics: Regulated by the coupling of bone-resorbing osteoclasts (myeloid lineage) and bone-forming osteoblasts (mesenchymal lineage).
• The RANK / RANKL / OPG Axis:
  • Osteoblasts and stromal cells express RANK Ligand (RANKL).
  • RANKL binds to the RANK receptor on osteoclast precursors, driving osteoclast differentiation, activation, and survival.
  • Osteoblasts also secrete Osteoprotegerin (OPG), a soluble decoy receptor that binds to RANKL, preventing it from activating RANK.
  • Estrogen Deficiency (Postmenopausal): Estrogen promotes OPG expression and induces osteoclast apoptosis. Following menopause, loss of estrogen upregulates RANKL and downregulates OPG, causing unrestrained osteoclastic bone resorption exceeding osteoblastic bone formation.
• Osteoporosis Definition and Diagnosis: Characterized by low bone mineral density (BMD) and microarchitectural deterioration of bone tissue, leading to bone fragility and increased fracture risk (vertebral compression, hip, Colles' distal radius fractures).
  • DEXA Bone Mineral Density T-Scores: Normal: $\text{T-score} \ge -1.0$; Osteopenia: $\text{T-score between } -1.0\text{ and } -2.5$; Osteoporosis: $\text{T-score} \le -2.5$.